MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-18-0000781
Megafine Pharma Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹310.01 Cr
▼ 5% YoY
Net profit · FY 2025
₹29.08 Cr
Net margin 9.4%
EBITDA · FY 2025
₹50.29 Cr
EBITDA margin 16.2%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹1.53 Cr
Issued & subscribed
Open charges
₹48 Cr
Satisfied ₹48.75 Cr
Company age
31 yrs
Est. 1995
Employees · EPFO
758
Provident fund records
About Megafine Pharma Private Limited
Data last updated:
Megafine Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 22 August 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1995PTC092028. Its GSTIN is 27AAACM7472M1ZZ (Maharashtra). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.53 Cr. It is led by directors including Shailesh Jethmal Sanghvi (Managing Director) and Rohit Brijmohan Mantri.
Its last annual general meeting (AGM) was held on 17 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹310.01 Cr, a decline of 5% compared to the previous year. For the same year it recorded a net profit of ₹29.08 Cr (net margin 9.4%) and EBITDA of ₹50.29 Cr (EBITDA margin 16.2%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 11% over five years.
The company has about 758 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Megafine. As per MCA filings, the company has open charges of ₹48 Cr and satisfied charges of ₹48.75 Cr on record. Court records list 23 cases involving the company, including 7 filed by the company and 15 filed against it; 3 cases are pending. The company has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Valiant Laboratories Limited with revenue of ₹338.77 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 152 overdue payments to 32 micro and small suppliers.
Megafine Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0000781). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website megafine.in.
Company Details of Megafine Pharma Private Limited
CIN U24239MH1995PTC092028
Registration Number 092028
Incorporation Date 22 August 1995
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 17 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-18-0000781
Key People
Shailesh Jethmal Sanghvi Managing Director Rohit Brijmohan Mantri Nominee Director Hari Prasshanth Nominee Director Recognitions & Rankings of Megafine Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address901 A Wing Naman Midtown, Senapati Bapat Marg Prabhadevi, Mumbai, Maharashtra, India – 400013
- IndustryPharma, API Manufacturers
Comprehensive company report
Megafine Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Megafine Pharma Private Limited
Megafine Pharma operates one associated brand: Megafine. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Company manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and also offering CDMO services for innovator and generic pharma companies | megafine.in |
Business Activity of Megafine Pharma Private Limited
The main business activity of Megafine Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Megafine Pharma Private Limited FY 2025 filings available
Megafine Pharma Private Limited reported revenue of ₹310.01 Cr (down 5% YoY) for FY 2025.
Revenue · FY 2025
₹310.01 Cr ▼ 5%
Net profit · FY 2025
₹29.08 Cr margin 9.4%
EBITDA · FY 2025
₹50.29 Cr margin 16.2%
Compounded Annual Growth Rate (CAGR) of Megafine Pharma Private Limited
Revenue CAGR growth
1 year
▼ 5%
3 years · compounded
▲ 7%
5 years · compounded
▲ 11%
EBITDA CAGR growth
1 year
▼ 13%
3 years · compounded
▲ 5%
5 years · compounded
▲ 69%
Revenue fell 5% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 11%. EBITDA fell 13% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Megafine Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹50.29 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹29.08 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Megafine Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 9.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Megafine Pharma are in the company report.
Premium access
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Megafine Pharma Private Limited
Megafine Pharma has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rohit Brijmohan Mantri Also directs: India Realty Excellence Fund II LLP, Symbiotec Biologics Private Limited, Symbiotec Zenfold Private Limited and 5 more | Nominee Director | 21 Feb 2025 | 1 Years 8 Months | Current |
| Shailesh Jethmal Sanghvi Also directs: Aar Cube Enterprise LLP, JMS Venture LLP | Managing Director | 22 Aug 1995 | 31 Years 1 Months | Current |
| Hari Prasshanth | Nominee Director | 06 Mar 2025 | 1 Years 7 Months | Current |
Peer Comparison of Megafine Pharma Private Limited
Megafine Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Valiant Laboratories Limited | ₹338.77 Cr (FY 2023) | •••• | •••• | 61.0% | •••• | Mumbai, Maharashtra, India |
| Mehta Api Private Limited | ₹325.77 Cr (FY 2025) | •••• | •••• | 36.0% | •••• | Mumbai, Maharashtra, India |
| Synergene Active Ingredients Private Limited | ₹319.93 Cr (FY 2024) | •••• | •••• | 37.0% | •••• | Hyderabad, Telangana, India |
| Mangalam Drugs and Organics Limited Listed | ₹318.73 Cr (FY 2025) | •••• | •••• | -14.0% | •••• | Mumbai, Maharashtra, India |
| Saraca Laboratories Limited | ₹310.45 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Hyderabad, Telangana, India |
| Megafine Pharma Private Limited this company | ₹310.01 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Mumbai, Maharashtra, India |
| Bal Pharma Limited Listed | ₹305.29 Cr (FY 2025) | •••• | •••• | -11.0% | •••• | Bangalore, Karnataka, India |
| Optrix Laboratories Private Limited | ₹304.7 Cr (FY 2020) | •••• | •••• | 43.0% | •••• | Hyderabad, Telangana, India |
| Ajinomoto Bio-Pharma Services India Private Limited | ₹301.41 Cr (FY 2025) | •••• | •••• | 56.0% | •••• | Anakapalle, Andhra Pradesh, India |
| Alembic Limited Listed | ₹296.78 Cr (FY 2025) | •••• | •••• | 40.0% | •••• | Vadodara, Gujarat, India |
| Anjan Drug Private Limited | ₹293.42 Cr (FY 2025) | •••• | •••• | -14.0% | •••• | Chengalpattu Dt, Tamil Nadu, India |
Peers are the five companies nearest above and the five nearest below Megafine Pharma by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Megafine Pharma Private Limited
Megafine Pharma Private Limited is audited by Jain Ambavat & Associates LLP for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Jain Ambavat & Associates LLP | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Megafine Pharma Private Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Megafine Pharma Private Limited
Open charges
₹48 Cr
Satisfied charges
₹48.75 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2012 | Hdfc Bank Limited | ₹8.5 Cr | Open |
| 13 Jun 2006 | State Bank of India | ₹39.5 Cr | Open |
| 22 Nov 2019 | Hdfc Bank Limited | ₹44.5 Cr | Satisfied |
| 29 Sep 2003 | Canara Bank | ₹2.7 Cr | Satisfied |
| 05 Jun 2002 | Canara Bank | ₹8 Lakh | Satisfied |
Total charge records: 9 View all charges
Deals & Funding of Megafine Pharma Private Limited
Megafine Pharma Private Limited has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025.
Total deals
8
Secondary share transfers
6
Funding round
1
Acquisition
1
Disclosed funding
₹1.2 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2025 | Acquisition | ₹460 Cr | Buyer: Motilal Oswal Private Equity |
| Sep 2022 | Secondary share transfer | Undisclosed | Seller: 4 individuals |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2015 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Hasmukh P Gandhi HUF, Dharmesh P Gandhi HUF, Mukesh J Sanghvi HUF Seller: 4 individuals |
Premium access
Full deal history
All 8 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Megafine Pharma Private Limited
Megafine Pharma Private Limited has 23 court cases on record: 7 filed by Megafine Pharma, 15 filed against it, 1 where it is another party. 3 cases are pending and 20 are disposed. Status as checked between 28 Sep 2026 and 04 Oct 2026.
Total cases
23
Filed by the company
7
Filed against the company
15
Pending
3
Disposed
20
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 17 | 10 | 2 |
| District courts | 6 | 5 | 1 |
Cases on record (5 of 23)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Company petition | Filed by the company against Super Fine Laboratories Private Limited and 1 other | Disposed |
| Bombay High Court | Appeal | Filed by the company against Super Fine Laboratories Private Limited and 1 other | Disposed |
| Bombay High Court | Tax appeal | Filed against the company by PR Commissioner of Income Tax 4 | Pending |
| High Court of Gujarat | Special civil application | Filed by the company against State of Gujarat | Pending |
| District court, Nashik, Maharashtra | Civil suit | Company is another party | Pending |
Premium access
Full case history
All 23 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Megafine Pharma Private Limited
Megafine Pharma Private Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 152 overdue payments to 32 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 32)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Jai Lakshmi Agro Chemicals Private Limited | •••• | •••• | •••• |
| Bombay Ammonia & Chemical Company | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 10 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Megafine Pharma Private Limited
Megafine Pharma Private Limited has a workforce of 758 employees as of Dec 12, 2024.
Employee count
758
Active EPFO establishments
2
Employee growth
0.4%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Megafine Pharma Private Limited
Megafine Pharma Private Limited has 6 board changes on record since 1995: 3 appointments and 3 cessations. The latest: Hari Prasshanth was appointed as Nominee Director on 06 Mar 2025.
AGM
Megafine Pharma Private Limited last Annual general meeting of members was held on 17 Sep 2025 as per latest MCA records.
Filing
Megafine Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Appointed
Hari Prasshanth was appointed as Nominee Director.
Appointed
Rohit Brijmohan Mantri was appointed as Nominee Director.
Charges
A charge registered on 22 Nov 2019 via Charge ID 100304683 with Hdfc Bank Limited was fully satisfied on 14 Aug 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 8.50 Cr registered on 26 Apr 2012 with Charge ID 10350830 was modified on 01 Aug 2024.
Charges
A charge with State Bank Of India of Rs. 39.50 Cr registered on 13 Jun 2006 with Charge ID 10007239 was modified on 20 Jul 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 44.50 Cr with Charge ID 100304683 was registered on 22 Nov 2019.
Ceased
Kunal Ashok Jhaveri ceased to be Additional Director.
Ceased
Ashok Kirtilal Jhaveri ceased to be Whole-Time Director.
Ceased
Hasmukh Purushottam Gandhi ceased to be Director.
Charges
A charge registered on 05 Jun 2002 via Charge ID 90160114 with Canara Bank was fully satisfied on 06 Jun 2012.
16 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Megafine Pharma Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Megafine Pharma Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Megafine Pharma Private Limited
Megafine Pharma has 3 GST registrations: 2 active and 1 cancelled or inactive.
Total GSTINs
3
Active
2
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACM7472M1ZZ | Maharashtra | Active | 01 Jul 2017 |
| 24AAACM7472M1Z5 | Gujarat | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Megafine Pharma Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Megafine Pharma Private Limited
Frequently Asked Questions about Megafine Pharma Private Limited
Megafine Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 22 August 1995 (31+ years old) and is registered under CIN U24239MH1995PTC092028.
Megafine Pharma reported revenue of ₹310.01 Cr for FY 2025 (down 5% YoY).
Megafine Pharma has 3 current directors:
- Shailesh Jethmal Sanghvi - Managing Director
- Rohit Brijmohan Mantri - Nominee Director
- Hari Prasshanth - Nominee Director
Megafine Pharma reported a net profit of ₹29.08 Cr (net margin 9.4%) and EBITDA of ₹50.29 Cr (EBITDA margin 16.2%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Megafine Pharma is 7% over three years and 11% over five years. In the latest year (FY 2025) revenue fell 5%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Megafine Pharma is 27AAACM7472M1ZZ, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 24AAACM7472M1Z5 (Gujarat).
The CIN (Corporate Identification Number) of Megafine Pharma is U24239MH1995PTC092028. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Megafine Pharma has 23 court cases on record: 7 filed by the company and 15 filed against it. 3 are pending. Most are in the high courts.
Megafine Pharma was incorporated on 22 August 1995, making it 31+ years old. It is registered with the Registrar of Companies, Mumbai.
Megafine Pharma has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025.
The peers of Megafine Pharma by revenue are Valiant Laboratories Limited, Mehta Api Private Limited, Synergene Active Ingredients Private Limited, Mangalam Drugs and Organics Limited, Saraca Laboratories Limited and 5 more, all in the Pharma industry (API Manufacturers).
Hari Prasshanth was appointed as Nominee Director on 06 Mar 2025. Rohit Brijmohan Mantri was appointed as Nominee Director on 21 Feb 2025. Kunal Ashok Jhaveri ceased to be Additional Director on 27 Sep 2019. Megafine Pharma has 6 board changes on record in total.